Botanix Pharmaceuticals Limited (ASX: BOT) is set to enter Phase 1b papulopustular rosacea study. BTX 1702, the new product, leverages Botanix’s proprietary drug delivery system PermetrexTM with synthetic cannabidiol. Recent mechanistic data generated by Botanix has demonstrated that synthetic cannabidiol exerts powerful anti-inflammatory and antimicrobial actions in skin.
- Study would commence in Q4 CY2019.
- BTX 1702 expands dermatology pipeline of the company.
- Anti-inflammatory and antimicrobial actions are critical in treating rosacea.
By 11:56 AM AEST, BOT was trading at A$0.25, no change relative to the previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.